MedTrace Logo

Cellulose Triacetate Dialyzer in Hemodiafiltration-online

NCT03105817 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2017-04-10

No results posted yet for this study

Summary

In post-dilution haemodiafiltration only synthetic membranes have been used to date.

The allergy problems described with these membranes require the development of other membranes capable of performing this treatment. We describe in vivo performance and behaviour of an asymmetric cellulose triacetate(ATA™) membrane, to identify its depurative effectiveness and ease of use in clinical practice, as well as evaluate its biocompatibility in a single haemodialysis session (acute biocompatibility) and after one month of treatment (chronic).

Conditions

  • Chronic Kidney Disease Requiring Chronic Dialysis

Interventions

DEVICE

Asymmetric cellulose triacetate (ATA™)

Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer

Sponsors & Collaborators

  • Hospital Universitario Infanta Leonor

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2016-07-10
Completion
2016-08-14

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03105817 on ClinicalTrials.gov